Seroatlas · Human Serome Atlas

GPR119

Glucose-dependent insulinotropic receptor

Also known as: GP119_HUMAN, GPCR2, hGPCR2

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q8TDV5
Gene: GPR119
Ensembl: ENSG00000147262
Chromosome: X
Canonical length: 335 aa
Protein class: G-protein coupled receptors, Predicted membrane proteins

OverviewNCBI Gene

This gene encodes a member of the rhodopsin subfamily of G-protein-coupled receptors that is expressed in the pancreas and gastrointestinal tract. The encoded protein is activated by lipid amides including lysophosphatidylcholine and oleoylethanolamide and may be involved in glucose homeostasis. This protein is a potential drug target in the treatment of type 2 diabetes.[provided by RefSeq, Jan 2010]

Canonical amino-acid sequenceUniProt

335 residues, UniProt reviewed canonical sequence.

>Q8TDV5|GPR119
     1  MESSFSFGVI LAVLASLIIA TNTLVAVAVL LLIHKNDGVS LCFTLNLAVA DTLIGVAISG
    61  LLTDQLSSPS RPTQKTLCSL RMAFVTSSAA ASVLTVMLIT FDRYLAIKQP FRYLKIMSGF
   121  VAGACIAGLW LVSYLIGFLP LGIPMFQQTA YKGQCSFFAV FHPHFVLTLS CVGFFPAMLL
   181  FVFFYCDMLK IASMHSQQIR KMEHAGAMAG GYRSPRTPSD FKALRTVSVL IGSFALSWTP
   241  FLITGIVQVA CQECHLYLVL ERYLWLLGVG NSLLNPLIYA YWQKEVRLQL YHMALGVKKV
   301  LTSFLLFLSA RNCGPERPRE SSCHIVTISS SEFDG

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against GPR119 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 7
Mean surface accessibility (rSASA): 0.33
Highest tissue expression: 1.9 nTPM

Expression across tissuesHPA

Tissue

pancreas: 1.9 nTPM
bone marrow: 0.4 nTPM
duodenum: 0.4 nTPM
stomach: 0.4 nTPM
rectum: 0.3 nTPM
skin: 0.3 nTPM

Single-cell type

pancreatic islet cells: 32 nCPM
neuroendocrine cells: 12 nCPM
sertoli cells: 1.1 nCPM
adrenal cortex cells: 0.4 nCPM
mucous neck cells: 0.4 nCPM
undifferentiated spermatogonia: 0.4 nCPM

Immune cell

basophil: 0.8 nTPM
neutrophil: 0.2 nTPM
NK-cell: 0.2 nTPM
classical monocyte: 0.1 nTPM
naive B-cell: 0.1 nTPM
naive CD4 T-cell: 0.1 nTPM

Brain region

cerebellum: 4.7 nTPM
white matter: 4.6 nTPM
pons: 3.7 nTPM
thalamus: 3.5 nTPM
cerebral cortex: 3.4 nTPM
medulla oblongata: 3.4 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.3
gnomAD pLI: 0.01
gnomAD missense Z: 1.24
DepMap mean gene effect: 0.27
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

G protein-coupled receptor, rhodopsin-like
GPCR, rhodopsin-like, 7TM
7 transmembrane receptor (rhodopsin family)
Glucose-dependent insulinotropic receptor

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads GPR119 as an antibody target. Whether an autoantibody or antibody against GPR119 could matter depends on whether native GPR119 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

GPR119 is annotated at the cell surface, where native GPR119 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label GPR119 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...